EPO

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Retrieved on: 
Monday, November 27, 2023
European Patent Office, SAN, National Cancer Institute, Menopause, European Patent Convention, EPO, Ovarian cancer, Vaccine, Cancer, Partnership, Patent, Pharmaceutical industry, Cleveland Clinic

SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."

Key Points: 
  • SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."
  • Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "Having recently been granted a U.S. patent for this novel ovarian cancer vaccine technology, we are delighted to receive the EPO's intention-to-grant notice, as a European patent would extend protection of the technology to additional potential markets."
  • The patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic.
  • Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.

BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ANNOUNCES INNOVATIVE PRODUCTS FOR 2024

Retrieved on: 
Monday, November 27, 2023
Carbon, Vision, Health savings account, Blue Cross, Travel, HealthEquity, Steward Health Care System, HSA, Pharmacy, Option, Atrius Health, Preferred provider organization, PPO, Glossary of music terminology, Calendar, Disability studies, EPO, Carbon Health, Medicine, HPN, Hospital, Common, Physician, Diabetes, Health, Health insurance

BOSTON, Nov. 27, 2023 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) today announced a suite of innovative new medical, pharmacy, dental and vision offerings that support the health plan's commitment to provide quality, affordable and equitable health care.

Key Points: 
  • BOSTON, Nov. 27, 2023 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) today announced a suite of innovative new medical, pharmacy, dental and vision offerings that support the health plan's commitment to provide quality, affordable and equitable health care.
  • Blue Cross announced the following new offerings:
    Exclusive Provider Organization (EPO) Plans: Blue Cross is offering new EPO plan options for fully insured customers and now will offer these plans to student groups.
  • The health plan will be the first in the market to offer an EPO plan to Massachusetts individuals and small groups.
  • Pharmacy Program through Sempre Health: To improve medication adherence and affordability for members with select chronic conditions including diabetes, Blue Cross is partnering with Sempre Health.

EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Retrieved on: 
Thursday, December 14, 2023
European Patent Office, Safety, European Patent Convention, Spacecraft, HPHA, ATAC, Amanitin, EPO, Research, Patent, FSE, Gesellschaft mit beschränkter Haftung

Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).

Key Points: 
  • Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).
  • Site-specific ATAC conjugates comprise a genetically engineered antibody to which Heidelberg Pharma’s proprietary amatoxin payloads can be coupled via specific linkers.
  • The European patent also covers a method for the synthesis of such conjugates as well as their use in the treatment of diseases.
  • Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are very pleased that this patent has been granted, as it protects essential aspects of our ATAC technology, as e.g.

PlantArcBio Secures Patent from European Patent Office for Its Innovative DIP™ Platform Advancing Global Food Security

Retrieved on: 
Thursday, November 9, 2023
Patent, Intellectual property, EPO, Nature, European Patent Office, Plant, Gene, TASE, European Patent Convention, Soybean, IP, Climate change, Agriculture, Antibiotics

This novel platform is designed to discover genes for improving traits in crops and solidifies PlantArcBio's commitment to revolutionizing global food security by adapting crops to the challenges posed by climate change and enhancing sustainability.

Key Points: 
  • This novel platform is designed to discover genes for improving traits in crops and solidifies PlantArcBio's commitment to revolutionizing global food security by adapting crops to the challenges posed by climate change and enhancing sustainability.
  • we are delighted to receive this additional patent that recognizes the intrinsic benefits of our innovative technology."
  • This groundbreaking platform was developed by PlantArcBio to provide a game-changing method for adapting agricultural crops to adverse environmental and biological conditions.
  • In line with its core strategy, PlantArcBio remains committed to fortifying its competitive edge through robust Intellectual Property (IP) protection.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Adrenoleukodystrophy, Patient, Serono, ALD, Plasma, AMN, Patent, Biomarker, Sumitomo Pharma, Diabetes, Merck, SGLT2, Jaguar 3.4 Litre, EPO, Pharmacokinetics, Male, DPP4, Disease, Prescription, Marshal of France, Pioglitazone, European Patent Office, EUR, United States patent law, Merck Serono, VLCFA, Safety, European Patent Convention, JPY, Estonia, Kidney, POC, Pharmaceutical industry, Imeglimin

Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.

Key Points: 
  • Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • Next Financial Press Release: Fourth Quarter 2023 Cash and Revenue update, on February 15, 2024

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Retrieved on: 
Tuesday, October 31, 2023
Patient, IND, PSA, Patent, Leukemia, Progression-free survival, Biomarker, Art, Ligand, World Intellectual Property Organization, CD15, Invention, CELL, Hematological Cancer Research Investment and Education Act, Patent Cooperation Treaty, Cell, EPO, Administration, China International Search and Rescue Team, Disease, ATCC (company), NK, Cancer, WIPO, CT, Blood, TME, General counsel, CD2, Immunosuppression, Hypoxia, Insurance, Vaccine, Pharmaceutical industry

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

Key Points: 
  • INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.
  • The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.
  • “Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company.
  • INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients.

ACA open enrollment starts Nov. 1, giving consumers a chance to compare health plans and potentially save money

Retrieved on: 
Monday, October 30, 2023
Health policy, Insurance, ACA, HMO, Family, Health maintenance organization, IRA, Care Act 2014, American Rescue Plan Act of 2021, EPO, PPO, Inflation Reduction Act of 2022, Inflation, POS, Health insurance, Nursing, Affordable Care Act, Marketplace

Minneapolis, MN, Oct. 30, 2023 (GLOBE NEWSWIRE) -- As the Affordable Care Act (also called ACA or Obamacare) open enrollment period nears, healthinsurance.org released tips today to help people compare plans and potentially save money.

Key Points: 
  • Minneapolis, MN, Oct. 30, 2023 (GLOBE NEWSWIRE) -- As the Affordable Care Act (also called ACA or Obamacare) open enrollment period nears, healthinsurance.org released tips today to help people compare plans and potentially save money.
  • Open enrollment for ACA plans starts Nov. 1, 2023, and ends Jan. 15, 2024, in most states.
  • “Open enrollment is an important time to review plans and see what’s best for you and your family,” said Louise Norris, a health policy analyst for healthinsurance.org .
  • For example, many POS and HMO plans require a referral to see a specialist, but some POS and HMO plans don’t.

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

Retrieved on: 
Monday, October 23, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Biopharma LLC, EPO, Ministry, Chronic kidney disease, Dialysis, PT, Anemia, Roche, CKD, Safety, Patient, Pharmaceutical industry, Medical device, Food, Korean

This milestone marks the first market approval for a drug originating from Genexine's research and development with KGbio.

Key Points: 
  • This milestone marks the first market approval for a drug originating from Genexine's research and development with KGbio.
  • Genexine, in collaboration with KGbio, has been co-developing Efepoetin alfa for CKD patients in both non-dialysis and dialysis settings.
  • Furthermore, a multinational Phase 3 clinical trial targeting dialysis patients is set to commence in the Q4 of 2023, spearheaded by Genexine and KGbio.
  • In 2020, Genexine and KGbio initiated phase 3 clinical trials for non-dialysis patients in a multinational setting, spanning seven countries across Asia and Oceania.

NUVVE UPDATES ITS V2G PATENT PORTFOLIO

Retrieved on: 
Friday, October 13, 2023
Patent, United Kingdom, Disclosure, Original equipment manufacturer, EVS, Transport, EV, Growth, European Patent Convention, SAN, EPO, Manasantha Nuvve, EVE, Rail transport, Renewable energy, Online shopping, Fireworks

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Nuvve Holding Corp. (Nasdaq: NVVE) ("Nuvve"), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, today commented on its newly granted European patent.

Key Points: 
  • SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Nuvve Holding Corp. (Nasdaq: NVVE) ("Nuvve"), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, today commented on its newly granted European patent.
  • Since its inception in 2010, Nuvve has invested significant resources in growing its V2G patent portfolio – and continues to do so today.
  • During the span from 2011 to 2017, the company expanded its patent holdings to include four early-industry V2G patents in the U.S. Today, Nuvve has numerous later-filed U.S. patent applications pending.
  • As such, Nuvve's V2G patent portfolio serves as a solid foundation that is deeply rooted in the intelligent integration of EVs into the grid from a wide variety of system-level perspectives.